The 9 most recent market catalysts affecting $NVCR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 1, 2026
Corporate Catalyst
Bearish
Impact 65
Novocure Reported Unauthorized Systems Access In Mid-August 2026, Exposing Internal Patient ID Numbers For Over 1,400 U.S. Records; No Medical Device Access Obtained, Operations, Systems Fully Functional
The unauthorized systems access at Novocure, exposing patient ID numbers, is a significant corporate catalyst. While operations remain functional and medical devices were not compr…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 85
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure announced impressive Q2 2026 results, surpassing analyst expectations for both revenue and earnings, and subsequently raised its full-year 2026 revenue and adjusted EBITDA…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52
HC Wainwright & Co. analyst Emily Bodnar maintained a 'Buy' rating on NovoCure and raised the price target from $46 to $52. This action signals a continued bullish sentiment from a…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 65
12 Health Care Stocks Moving In Thursday's Intraday Session
This 8-K filing, presented as a Benzinga article, highlights significant intraday price fluctuations for a selection of healthcare stocks. The primary drivers identified for some o…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 85
NovoCure shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline represents a significant positive corporate catalyst for NovoCure. Better-than-expected earnings and, more importantly, a raised long-term sales guidance (FY26) signa…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 85
Transcript: NovoCure Q2 2026 Earnings Conference Call
NovoCure's Q2 2026 earnings call transcript reveals record net revenues of $184 million, a 16% year-over-year increase, driven by growth in Optune Gio, Lua, and Pax. The company al…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 75
NovoCure Raises FY2026 Sales Guidance from $690.000M-$710.000M to $710.000M-$725.000M vs $708.743M Est
NovoCure (NVCR) has filed an 8-K to announce an upward revision to its fiscal year 2026 sales guidance. The new range of $710 million to $725 million is higher than the previous $6…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
NovoCure Q2 EPS $(0.13) Beats $(0.33) Estimate, Sales $183.584M Beat $172.437M Estimate
NovoCure's Q2 earnings report shows a significant beat on both EPS and sales estimates, with losses narrowing considerably compared to the previous year. This indicates stronger op…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 55
JP Morgan Reinstates Neutral on NovoCure, Announces $17 Price Target
JP Morgan analyst Jessica Fye has reinstated coverage on NovoCure (NVCR) with a 'Neutral' rating and a $17 price target. This event is significant because analyst ratings and price…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.